Cortical inhibitory deficits in premanifest and early Huntington's disease

Behavioural Brain Research

Volumn 296, Issue , 2016, Pages 311-317

  Philpott, April L ^a   Cummins, Tarrant D R ^a   Bailey, Neil W ^b   Churchyard, Andrew ^c   Fitzgerald, Paul B ^b   Georgiou Karistianis, Nellie ^a  

^a MONASH UNIVERSITY   (Australia)

^b Australia   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

Cortical inhibition; Corticostriatal; GABA; Pathophysiological mechanism; Premanifest Huntington's disease; Transcranial magnetic stimulation

Indexed keywords

ABDUCTOR POLLICIS BREVIS MUSCLE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE CLASSIFICATION; ELECTROMYOGRAPHY; FEMALE; HAND MUSCLE; HUMAN; HUNTINGTON CHOREA; MALE; MENTAL DISEASE; NERVE EXCITABILITY; PATHOGENESIS; PHENOTYPE; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; METABOLISM; MIDDLE AGED; MOTOR CORTEX; NERVE CELL INHIBITION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRODROMAL SYMPTOM;

4 AMINOBUTYRIC ACID;

ADULT; AGED; ELECTROMYOGRAPHY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR CORTEX; NEURAL INHIBITION; PRODROMAL SYMPTOMS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84943403051     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.09.030     Document Type: Article

References (52)

1. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
2. Tabrizi S.J., Langbehn D.R., Leavitt B.R., Roos R.A.C., Durr A., Craufurd D., et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009, 8:791-801.
3. Stout J.C., Paulsen J.S., Queller S., Solomon A.C., Whitlock K.B., Campbell J.C., et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011, 25:1-14.
4. Davies C.H., Davies S.N., Collingridge G.L. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J. Physiol. (Lond.) 1990, 424:513-531.
5. Valls-Solé J., Pascual-Leone A., Wassermann E.M., Hallett M. Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr. Clin. Neurophysiol./Evoked Potentials Sect. 1992, 85:355-364.
6. Werhahn K.J., Kunesch E., Noachtar S., Benecke R., Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J. Physiol. (Lond.) 1999, 517:591-597.
7. Philpott A.L., Fitzgerald P.B., Cummins T.D.R., Georgiou-Karistianis N. Transcranial magnetic stimulation as a tool for understanding neurophysiology in Huntington's disease: a review. Neurosci. Biobehav. Rev. 2013, 37:1420-1433.
8. Rosas H.D., Hevelone N.D., Zaleta A.K., Greve D.N., Salat D.H., Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005, 65:745-747.
9. Nardone R., Lochner P., Marth R., Ausserer H., Bratti A., Tezzon F. Abnormal intracortical facilitation in early-stage Huntington's disease. Clin. Neurophysiol. 2007, 118:1149-1154.
10. Modugno N., Currà A., Giovannelli M., Priori A., Squitieri F., Ruggieri S., et al. The prolonged cortical silent period in patients with Huntington's disease. Clin. Neurophysiol. 2001, 112:1470-1474.
11. Priori A., Polidori L., Rona S., Manfredi M., Berardelli A. Spinal and cortical inhibition in Huntington's chorea. Mov. Disord. 2000, 15:938-946.
12. Abbruzzese G., Buccolieri A., Marchese R., Trompetto C., Mandich P., Schieppati M. Intracortical inhibition and facilitation are abnormal in Huntington's disease: a paired magnetic stimulation study. Neurosci. Lett. 1997, 228:87-90.
13. Tegenthoff M., Vorgerd M., Juskowiak F., Roos V., Malin J.P. Postexcitatory inhibition after transcranial magnetic single and double brain stimulation in Huntington's disease. Electroencephalogr. Clin. Neurophysiol. 1996, 101:298-303.
14. Schippling S., Schneider S.A., Bhatia K.P., Münchau A., Rothwell J.C., Tabrizi S.J., et al. Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol. Psychiatry 2009, 65:959-965.
15. Cepeda C., Wu N., André V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
16. Gu X., Li C., Wei W., Lo V., Gong S., Li S.-H., et al. Pathological cell-cel interactions elicited by a neuropathogenic form of mutant huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005, 46:433-444.
17. Orth M., Schippling S., Schneider S.A., Bhatia K.P., Talelli P., Tabrizi S.J., et al. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J. Neurol. Neurosurg. Psychiatry 2010, 81:267-270.
18. Nguyen L., Bradshaw J.L., Stout J.C., Croft R.J., Georgiou-Karistianis N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. Brain Res. Rev. 2010, 64:177-194.
19. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci. 2010, 33:513-523.
20. Jung P., Ziemann U. Differences of the ipsilateral silent period in small hand muscles. Muscle Nerve 2006, 34:431-436.
21. Nelson H.E., Willison J., Owen A.M. National adult reading test, 2nd edition. Int. J. Geriatr. Psychiatry 1992, 7:533.
22. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., Hayden M.R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 2004, 65:267-277.
23. Penney J.B., Vonsattel J.-P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 1997, 41:689-692.
24. Rossi S., Hallett M., Rossini P.M., Pascual-Leone A. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin. Neurophysiol. 2009, 120:2008-2039.
25. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12:637-649.
26. Stout J.C., Jones R., Labuschagne I., O'Regan A.M., Say M.J., Dumas E.M., et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2012, 83:687-694.
27. Georgiou-Karistianis N., Stout J.C., Domínguez D.J.F., Carron S.P., Ando A., Churchyard A., et al. Functional magnetic resonance imaging of working memory in Huntington's disease: cross-sectional data from the IMAGE-HD study. Hum. Brain Mapp. 2014, 35:1847-1864.
28. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Therapy and Clinical Interpretation 1985, Neuoropsychological Press. A.Z. Tucson (Ed.).
29. Smith A. Symbol Digit Modality Test (SDMT): Manual (Revised) 1982, Psychological Services, Los Angeles.
30. Hinton S.C., Paulsen J.S., Hoffmann R.G., Reynolds N.C., Zimbelman J.L., Rao S.M. Motor timing variability increases in preclinical Huntington's disease patients as estimated onset of motor symptoms approaches. J. Int. Neuropsychol. Soc. 2007, 13:539-543.
31. Georgiou-Karistianis N., Long J.D., Lourens S.G., Stout J.C., Mills J.A., Paulsen J.S. Movement sequencing in Huntington disease. World J. Biol. Psychiatry 2014, 15:459-471.
32. Beck A.T., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory-II 1996, Psychological Corporation, San Antonio, TX.
33. Beck A.T., Steer R.A. Manual for the Beck Anxiety Inventory 1990, Psychological Corporation, San Antonio, TX.
34. Grace J., Mallory P.F. Frontal Systems Behavior Scale: Professional Manual 2001, Psychological Assessment Resources, Lutz.
35. Rossini P.M., Barker A.T., Berardelli A., Caramia M.D., Caruso G., Cracco R.Q., et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr. Clin. Neurophysiol. 1994, 91:79-92.
36. Orth M., Rothwell J.C. The cortical silent period: intrinsic variability and relation to the waveform of the transcranial magnetic stimulation pulse. Clin. Neurophysiol. 2004, 115:1076-1082.
37. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., et al. Corticocortical inhibition in human motor cortex. J. Physiol. (Lond.) 1993, 471:501-519.
38. Wexler N.S. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3498-3503.
39. Wassermann E.M., Samii A., Mercuri B., Ikoma K., Oddo D., Grill S., et al. Responses to paired transcranial magnetic stimuli in resting, active, and recently activated muscles. Exp. Brain Res. 1996, 109:158-163.
40. Brusa L., Versace V., Koch G., Bernardi G., Iani C., Stanzione P., et al. Improvement of choreic movements by 1Hz repetitive transcranial magnetic stimulation in Huntington's disease patients. Ann. Neurol. 2005, 58:655-656.
41. Lorenzano C., Dinapoli L., Gilio F., Suppa A., Bagnato S., Currà A., et al. Motor cortical excitability studied with repetitive transcranial magnetic stimulation in patients with Huntington's disease. Clin. Neurophysiol. 2006, 117:1677-1681.
42. Priori A., Berardelli A., Inghilleri M., Polidori L., Manfredi M. Electromyographic silent period after transcranial brain stimulation in Huntington's disease. Mov. Disord. 1994, 9:178-182.
43. Li J.-Y., Plomann M., Brundin P. Huntington's disease: a synaptopathy?. Trends Mol. Med. 2003, 9:414-420.
44. Raymond L.A., André V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
45. Poudel G.R., Egan G.F., Churchyard A., Chua P., Stout J.C., Georgiou-Karistianis N. Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. J. Psychiatry Neurosci.: JPN 2014, 39:87-96.
46. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
47. Cummings D.M., André V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., et al. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 2009, 29:10371-10386.
48. Coxon J.P., Stinear C.M., Byblow W.D. Intracortical inhibition during volitional inhibition of prepared action. J. Neurophysiol. 2006, 95:3371-3383.
49. Sanger T.D., Garg R.R., Chen R. Interactions between two different inhibitory systems in the human motor cortex. J. Physiol. (Lond.) 2001, 530:307-317.
50. McCormick D.A. Neurotransmitter actions in the thalamus and cerebral cortex. J. Clin. Neurophysiol. 1992, 9:212-223.
51. Allen K.L., Waldvogel H.J., Glass M., Faull R.L.M. Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. J. Chem. Neuroanat. 2009, 37:266-281.
52. Cepeda C., Hurst R.S., Calvert C.R., Hernández-Echeagaray E., Nguyen O.K., Jocoy E., et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 2003, 23:961-969.